{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:34:12Z","timestamp":1777584852595,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00592-018-1236-6","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T02:53:41Z","timestamp":1539140021000},"page":"289-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2407-9860","authenticated-orcid":false,"given":"Giulio","family":"Marchesini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizio","family":"Pasqualetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Anichini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Memoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Ponzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Resi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Serviddio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Zanette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"key":"1236_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S2213-8587(17)30097-9","volume":"5","author":"C Bommer","year":"2017","unstructured":"Bommer C, Heesemann E, Sagalova V et al (2017) The global economic burden of diabetes in adults aged 20\u201379\u00a0years: a cost-of-illness study. Lancet Diabetes Endocrinol 5:423\u2013430. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(17)30097-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1236_CR2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.numecd.2016.05.002","volume":"26","author":"E Pagano","year":"2016","unstructured":"Pagano E, De Rosa M, Rossi E et al (2016) The relative burden of diabetes complications on healthcare costs: the population-based CINECA-SID ARNO Diabetes Observatory. Nutr Metab Cardiovasc Dis 26:944\u2013950. \n                    https:\/\/doi.org\/10.1016\/j.numecd.2016.05.002","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1236_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2337\/dc14-1687","volume":"38","author":"X Zhuo","year":"2015","unstructured":"Zhuo X, Zhang P, Kahn HS et al (2015) Change in medical spending attributable to diabetes: national data from 1987 to 2011. Diabetes Care 38:581\u2013587. \n                    https:\/\/doi.org\/10.2337\/dc14-1687","journal-title":"Diabetes Care"},{"key":"1236_CR4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.numecd.2014.07.014","volume":"24","author":"S Montilla","year":"2014","unstructured":"Montilla S, Marchesini G, Sammarco A et al (2014) Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutr Metab Cardiovasc Dis 24:1346\u20131353. \n                    https:\/\/doi.org\/10.1016\/j.numecd.2014.07.014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1236_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc15-1194","volume":"39","author":"AJ Farmer","year":"2016","unstructured":"Farmer AJ, Rodgers LR, Lonergan M et al (2016) Adherence to oral glucose-lowering therapies and associations with 1-year HbA1c: a retrospective cohort analysis in a large primary care database. Diabetes Care 39:258\u2013263. \n                    https:\/\/doi.org\/10.2337\/dc15-1194","journal-title":"Diabetes Care"},{"key":"1236_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/dme.12651","volume":"32","author":"I Krass","year":"2015","unstructured":"Krass I, Schieback P, Dhippayom T (2015) Adherence to diabetes medication: a systematic review. Diabet Med 32:725\u2013737. \n                    https:\/\/doi.org\/10.1111\/dme.12651","journal-title":"Diabet Med"},{"key":"1236_CR7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2147\/PPA.S136639","volume":"11","author":"T Kennedy-Martin","year":"2017","unstructured":"Kennedy-Martin T, Boye KS, Peng X (2017) Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. Patient Prefer Adherence 11:1103\u20131117. \n                    https:\/\/doi.org\/10.2147\/PPA.S136639","journal-title":"Patient Prefer Adherence"},{"key":"1236_CR8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/1060028014526362","volume":"48","author":"LE Egede","year":"2014","unstructured":"Egede LE, Gebregziabher M, Echols C et al (2014) Longitudinal effects of medication nonadherence on glycemic control. Ann Pharmacother 48:562\u2013570. \n                    https:\/\/doi.org\/10.1177\/1060028014526362","journal-title":"Ann Pharmacother"},{"key":"1236_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1108\/S0731-2199(2010)0000022010","volume":"22","author":"WE Encinosa","year":"2010","unstructured":"Encinosa WE, Bernard D, Dor A (2010) Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res 22:151\u2013173","journal-title":"Adv Health Econ Health Serv Res"},{"key":"1236_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/01.mlr.0000163641.86870.af","volume":"43","author":"MC Sokol","year":"2005","unstructured":"Sokol MC, McGuigan KA, Verbrugge RR et al (2005) Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43:521\u2013530","journal-title":"Med Care"},{"key":"1236_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s13300-013-0034-y","volume":"4","author":"LE Garcia-Perez","year":"2013","unstructured":"Garcia-Perez LE, Alvarez M, Dilla T et al (2013) Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 4:175\u2013194. \n                    https:\/\/doi.org\/10.1007\/s13300-013-0034-y","journal-title":"Diabetes Ther"},{"key":"1236_CR12","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.2337\/dc18-S008","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association (2018) 8. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2018. Diabetes Care 41:S73\u2013S85. \n                    https:\/\/doi.org\/10.2337\/dc18-S008","journal-title":"Diabetes Care"},{"key":"1236_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s13300-012-0006-7","volume":"3","author":"S Matthaei","year":"2012","unstructured":"Matthaei S, Reaney M, Mathieu C et al (2012) Patients with type 2 diabetes initiating exenatide twice daily or insulin in clinical practice: CHOICE study. Diabetes Ther 3:6. \n                    https:\/\/doi.org\/10.1007\/s13300-012-0006-7","journal-title":"Diabetes Ther"},{"key":"1236_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1477-7525-11-217","volume":"11","author":"M Reaney","year":"2013","unstructured":"Reaney M, Mathieu C, Ostenson CG et al (2013) Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study. Health Qual Life Outcomes 11:217. \n                    https:\/\/doi.org\/10.1186\/1477-7525-11-217","journal-title":"Health Qual Life Outcomes"},{"key":"1236_CR15","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.clinthera.2017.11.001","volume":"39","author":"M Yu","year":"2017","unstructured":"Yu M, Mody R, Lando LF et al (2017) Characteristics associated with the choice of first injectable therapy among US patients with type 2 diabetes. Clin Ther 39:2399\u20132408. \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2017.11.001","journal-title":"Clin Ther"},{"key":"1236_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/DMSO.S71923","volume":"8","author":"DF Kruger","year":"2015","unstructured":"Kruger DF, LaRue S, Estepa P (2015) Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. Diabetes Metab Syndr Obes 8:49\u201356. \n                    https:\/\/doi.org\/10.2147\/DMSO.S71923","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1236_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","volume":"32","author":"MD Clark","year":"2014","unstructured":"Clark MD, Determann D, Petrou S et al (2014) Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics 32:883\u2013902. \n                    https:\/\/doi.org\/10.1007\/s40273-014-0170-x","journal-title":"Pharmacoeconomics"},{"key":"1236_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1185\/03007995.2015.1117433","volume":"32","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Nguyen H, Posner J et al (2016) A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Curr Med Res Opin 32:251\u2013262. \n                    https:\/\/doi.org\/10.1185\/03007995.2015.1117433","journal-title":"Curr Med Res Opin"},{"key":"1236_CR19","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2147\/PPA.S90842","volume":"9","author":"HL Gelhorn","year":"2015","unstructured":"Gelhorn HL, Poon JL, Davies EW et al (2015) Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naive type 2 diabetes patients in the UK. Patient Prefer Adherence 9:1611\u20131622. \n                    https:\/\/doi.org\/10.2147\/PPA.S90842","journal-title":"Patient Prefer Adherence"},{"key":"1236_CR20","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2337\/dc13-2527","volume":"37","author":"TS Purnell","year":"2014","unstructured":"Purnell TS, Joy S, Little E et al (2014) Patient preferences for noninsulin diabetes medications: a systematic review. Diabetes Care 37:2055\u20132062. \n                    https:\/\/doi.org\/10.2337\/dc13-2527","journal-title":"Diabetes Care"},{"key":"1236_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jama.2016.9400","volume":"316","author":"SC Palmer","year":"2016","unstructured":"Palmer SC, Mavridis D, Nicolucci A et al (2016) Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316:313\u2013324. \n                    https:\/\/doi.org\/10.1001\/jama.2016.9400","journal-title":"JAMA"},{"key":"1236_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2165\/11539650-000000000-00000","volume":"3","author":"D Marshall","year":"2010","unstructured":"Marshall D, Bridges JF, Hauber B et al (2010) Conjoint analysis applications in health\u2014How are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient 3:249\u2013256. \n                    https:\/\/doi.org\/10.2165\/11539650-000000000-00000","journal-title":"Patient"},{"key":"1236_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s13300-017-0237-8","volume":"8","author":"L Qin","year":"2017","unstructured":"Qin L, Chen S, Flood E et al (2017) Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-experienced patients with type 2 diabetes mellitus: a preference study in Germany and the United Kingdom. Diabetes Ther 8:335\u2013353. \n                    https:\/\/doi.org\/10.1007\/s13300-017-0237-8","journal-title":"Diabetes Ther"},{"key":"1236_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s13300-017-0230-2","volume":"8","author":"L Qin","year":"2017","unstructured":"Qin L, Chen S, Flood E et al (2017) Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-naive patients with type 2 diabetes mellitus: a multinational preference study. Diabetes Ther 8:321\u2013334. \n                    https:\/\/doi.org\/10.1007\/s13300-017-0230-2","journal-title":"Diabetes Ther"},{"key":"1236_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1465903:1-8","author":"LS Matza","year":"2018","unstructured":"Matza LS, Boye KS, Currie BM et al (2018) Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes. Curr Med Res Opin. \n                    https:\/\/doi.org\/10.1080\/03007995.2018.1465903:1-8\n                    \n                  . doi: 10.1080\/03007995.2018.1465903","journal-title":"Curr Med Res Opin"},{"key":"1236_CR26","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1186\/s12913-017-2648-7","volume":"17","author":"LS Matza","year":"2017","unstructured":"Matza LS, Boye KS, Stewart KD et al (2017) Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Serv Res 17:774. \n                    https:\/\/doi.org\/10.1186\/s12913-017-2648-7","journal-title":"BMC Health Serv Res"},{"key":"1236_CR27","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s13300-017-0326-8","volume":"8","author":"C Mansfield","year":"2017","unstructured":"Mansfield C, Sikirica MV, Pugh A et al (2017) Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther 8:1365\u20131378. \n                    https:\/\/doi.org\/10.1007\/s13300-017-0326-8","journal-title":"Diabetes Ther"},{"key":"1236_CR28","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.2337\/dc18-S006","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association (2018) 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care 41:S55\u2013S64. \n                    https:\/\/doi.org\/10.2337\/dc18-S006","journal-title":"Diabetes Care"},{"key":"1236_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40271-017-0225-0","volume":"10","author":"A Ryden","year":"2017","unstructured":"Ryden A, Chen S, Flood E et al (2017) Discrete choice experiment attribute selection using a multinational interview study: treatment features important to patients with type 2 diabetes mellitus. Patient 10:475\u2013487. \n                    https:\/\/doi.org\/10.1007\/s40271-017-0225-0","journal-title":"Patient"},{"key":"1236_CR30","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2018.3024","volume":"319","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 319:1580\u20131591. \n                    https:\/\/doi.org\/10.1001\/jama.2018.3024","journal-title":"JAMA"},{"key":"1236_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jval.2017.07.001","volume":"21","author":"EM Janssen","year":"2018","unstructured":"Janssen EM, Hauber AB, Bridges JFP (2018) Conducting a discrete-choice experiment study following recommendations for good research practices: an application for eliciting patient preferences for diabetes treatments. Value Health 21:59\u201368. \n                    https:\/\/doi.org\/10.1016\/j.jval.2017.07.001","journal-title":"Value Health"},{"key":"1236_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/BF03327581","volume":"12","author":"G Marano","year":"2007","unstructured":"Marano G, Cuzzolaro M, Vetrone G et al (2007) Further validation study of the Body Uneasiness Test (BUT) in a clinical sample of 1922 adult obese subjects. Eat Weight Disord 12:70\u201382","journal-title":"Eat Weight Disord"},{"key":"1236_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/03007995.2016.1253553","volume":"33","author":"EM Flood","year":"2017","unstructured":"Flood EM, Bell KF, de la Cruz MC et al (2017) Patient preferences for diabetes treatment attributes and drug classes. Curr Med Res Opin 33:261\u2013268. \n                    https:\/\/doi.org\/10.1080\/03007995.2016.1253553","journal-title":"Curr Med Res Opin"},{"key":"1236_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s13300-015-0094-2","volume":"6","author":"AB Hauber","year":"2015","unstructured":"Hauber AB, Tunceli K, Yang JC et al (2015) A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus. Diabetes Ther 6:75\u201384. \n                    https:\/\/doi.org\/10.1007\/s13300-015-0094-2","journal-title":"Diabetes Ther"},{"key":"1236_CR35","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10198-015-0750-5","volume":"17","author":"A Muhlbacher","year":"2016","unstructured":"Muhlbacher A, Bethge S (2016) What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. Eur J Health Econ 17:1125\u20131140. \n                    https:\/\/doi.org\/10.1007\/s10198-015-0750-5","journal-title":"Eur J Health Econ"},{"key":"1236_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.numecd.2009.10.009","volume":"21","author":"G Marchesini","year":"2011","unstructured":"Marchesini G, Forlani G, Rossi E et al (2011) The direct economic cost of pharmacologically-treated diabetes in Italy-2006. The ARNO observatory. Nutr Metab Cardiovasc Dis 21:339\u2013346. \n                    https:\/\/doi.org\/10.1016\/j.numecd.2009.10.009","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1236_CR37","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296\u20131310","journal-title":"Clin Ther"},{"key":"1236_CR38","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.2147\/PPA.S91553","volume":"9","author":"NS Abraham","year":"2015","unstructured":"Abraham NS, Naik AD, Street RL Jr et al (2015) Complex antithrombotic therapy: determinants of patient preference and impact on medication adherence. Patient Prefer Adherence 9:1657\u20131668. \n                    https:\/\/doi.org\/10.2147\/PPA.S91553","journal-title":"Patient Prefer Adherence"},{"key":"1236_CR39","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40273-013-0089-7","volume":"31","author":"SM Joy","year":"2013","unstructured":"Joy SM, Little E, Maruthur NM et al (2013) Patient preferences for the treatment of type 2 diabetes: a scoping review. Pharmacoeconomics 31:877\u2013892. \n                    https:\/\/doi.org\/10.1007\/s40273-013-0089-7","journal-title":"Pharmacoeconomics"},{"key":"1236_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1177\/0145721705274927","volume":"31","author":"MK Rhee","year":"2005","unstructured":"Rhee MK, Slocum W, Ziemer DC et al (2005) Patient adherence improves glycemic control. Diabetes Educ 31:240\u2013250. \n                    https:\/\/doi.org\/10.1177\/0145721705274927","journal-title":"Diabetes Educ"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-018-1236-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-018-1236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-018-1236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T19:20:29Z","timestamp":1570648829000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-018-1236-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["1236"],"URL":"https:\/\/doi.org\/10.1007\/s00592-018-1236-6","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"assertion":[{"value":"6 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and\/or animal rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}